ADAGENE ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF ADG138, A NOVEL HER2XCD3 DOUBLE-MASKED BISPECIFIC T-CELL ENGAGER

Reuters · 1d ago

Please log in to view news